129 related articles for article (PubMed ID: 14684851)
1. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth.
Carey JL; Sasur LM; Kawakubo H; Gupta V; Christian B; Bailey PM; Maheswaran S
Mol Endocrinol; 2004 Mar; 18(3):696-707. PubMed ID: 14684851
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
Tomari K; Kumagai T; Shimizu T; Takeda K
Int J Mol Med; 2005 Feb; 15(2):253-8. PubMed ID: 15647840
[TBL] [Abstract][Full Text] [Related]
3. E2F activity is biphasically regulated by androgens in LNCaP cells.
Hofman K; Swinnen JV; Verhoeven G; Heyns W
Biochem Biophys Res Commun; 2001 Apr; 283(1):97-101. PubMed ID: 11322773
[TBL] [Abstract][Full Text] [Related]
4. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
5. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
Fribourg AF; Knudsen KE; Strobeck MW; Lindhorst CM; Knudsen ES
Cell Growth Differ; 2000 Jul; 11(7):361-72. PubMed ID: 10939590
[TBL] [Abstract][Full Text] [Related]
6. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP.
Zhang Z; Zhao Y; Batres Y; Lin MF; Ying SY
Biochem Biophys Res Commun; 1997 May; 234(2):362-5. PubMed ID: 9177276
[TBL] [Abstract][Full Text] [Related]
7. Unique natural antioxidants (NAOs) and derived purified components inhibit cell cycle progression by downregulation of ppRb and E2F in human PC3 prostate cancer cells.
Bakshi S; Bergman M; Dovrat S; Grossman S
FEBS Lett; 2004 Aug; 573(1-3):31-7. PubMed ID: 15327971
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.
Tyagi A; Agarwal C; Agarwal R
Mol Cancer Ther; 2002 May; 1(7):525-32. PubMed ID: 12479270
[TBL] [Abstract][Full Text] [Related]
9. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells.
Dalkin AC; Gilrain JT; Bradshaw D; Myers CE
Endocrinology; 1996 Dec; 137(12):5230-5. PubMed ID: 8940339
[TBL] [Abstract][Full Text] [Related]
10. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells.
Burdette JE; Jeruss JS; Kurley SJ; Lee EJ; Woodruff TK
Cancer Res; 2005 Sep; 65(17):7968-75. PubMed ID: 16140969
[TBL] [Abstract][Full Text] [Related]
11. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells.
Chinni SR; Li Y; Upadhyay S; Koppolu PK; Sarkar FH
Oncogene; 2001 May; 20(23):2927-36. PubMed ID: 11420705
[TBL] [Abstract][Full Text] [Related]
12. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.
Huang H; Zegarra-Moro OL; Benson D; Tindall DJ
Oncogene; 2004 Mar; 23(12):2161-76. PubMed ID: 14676836
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cell-cycle effectors of proliferation in bladder tumor epithelial cells by the p75NTR tumor suppressor.
Khwaja F; Djakiew D
Mol Carcinog; 2003 Mar; 36(3):153-60. PubMed ID: 12619038
[TBL] [Abstract][Full Text] [Related]
14. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
Lynch RL; Konicek BW; McNulty AM; Hanna KR; Lewis JE; Neubauer BL; Graff JR
Mol Cancer Res; 2005 Mar; 3(3):163-9. PubMed ID: 15798096
[TBL] [Abstract][Full Text] [Related]
15. Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone beta subunit in mouse gonadotrope cells.
Bernard DJ
Mol Endocrinol; 2004 Mar; 18(3):606-23. PubMed ID: 14701940
[TBL] [Abstract][Full Text] [Related]
16. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP.
Wang QF; Tilly KI; Tilly JL; Preffer F; Schneyer AL; Crowley WF; Sluss PM
Endocrinology; 1996 Dec; 137(12):5476-83. PubMed ID: 8940374
[TBL] [Abstract][Full Text] [Related]
17. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis.
Kuwajerwala N; Cifuentes E; Gautam S; Menon M; Barrack ER; Reddy GP
Cancer Res; 2002 May; 62(9):2488-92. PubMed ID: 11980638
[TBL] [Abstract][Full Text] [Related]
19. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function.
Bartholin L; Maguer-Satta V; Hayette S; Martel S; Gadoux M; Corbo L; Magaud JP; Rimokh R
Oncogene; 2002 Mar; 21(14):2227-35. PubMed ID: 11948405
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
